Literature DB >> 3663384

Apraxia in a patient with atypical cerebral dominance.

S Z Rapcsak1, L J Gonzalez Rothi, K M Heilman.   

Abstract

Liepmann postulated that the left hemisphere of right-handed persons contains the "movement formulas" that control purposeful skilled movements of the limbs on both sides of the body. Accordingly, in right-handers apraxia should follow damage to the left hemisphere, whereas right hemisphere damage should not lead to apraxia. Although this is generally true, we recently examined a right-handed man who after a right hemispheric stroke became aphasic and apraxic with his nonparalyzed right hand. Our observations suggest that the right hemisphere of this right-handed man made a critical contribution to the planning and execution of skilled movements. This case provides evidence that right-handers should not be considered a homogeneous group in terms of cerebral motor dominance and that contrary to Liepmann's postulate, hemispheric dominance for the control of skilled movements does not entirely determine handedness.

Entities:  

Mesh:

Year:  1987        PMID: 3663384     DOI: 10.1016/0278-2626(87)90139-4

Source DB:  PubMed          Journal:  Brain Cogn        ISSN: 0278-2626            Impact factor:   2.310


  3 in total

1.  Cerebral lateralization of praxis in right- and left-handedness: same pattern, different strength.

Authors:  Guy Vingerhoets; Frederic Acke; Ann-Sofie Alderweireldt; Jo Nys; Pieter Vandemaele; Eric Achten
Journal:  Hum Brain Mapp       Date:  2011-04-15       Impact factor: 5.038

Review 2.  A neuropsychological perspective on the link between language and praxis in modern humans.

Authors:  Agnes Roby-Brami; Joachim Hermsdörfer; Alice C Roy; Stéphane Jacobs
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-01-12       Impact factor: 6.237

3.  Slowly progressive apraxia in Alzheimer's disease.

Authors:  R C Green; F C Goldstein; S S Mirra; N P Alazraki; J L Baxt; R A Bakay
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-09       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.